Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Cyril Leung

Interventional Cardiology Huntington Beach, CA Medical Doctor

NPI 1134254345 CMS profile 594670

7636 Park Bay Dr, Huntington Beach, CA 92648

Open in the dashboard

General payments

$2,239

98 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cyril Leung of Huntington Beach, CA is reported in the CMS Open Payments database as having received $2,239 across 98 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 21st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $388 15
2024 General $522 25
2023 General $793 38
2022 General $372 18
2021 General $24 1
2020 General $140 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cyril Leung
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Cyril Leung were reported at $388. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Cyril Leung Interventional Cardiology median Middle half National median
2019 $0 $1,097 $329–$3,048 $163
2020 $140 $473 $161–$1,480 $114
2021 $24 $677 $233–$1,827 $132
2022 $372 $978 $333–$2,724 $149
2023 $793 $1,136 $382–$2,986 $160
2024 $522 $1,181 $395–$3,326 $164
2025 $388 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $410 18 payments
  2. AstraZeneca Pharmaceuticals LP $274 14 payments
  3. Novartis Pharmaceuticals Corporation $267 14 payments
  4. Novo Nordisk Inc $264 13 payments
  5. Merck Sharp & Dohme Corporation $214 9 payments
  6. Pfizer Inc. $175 7 payments
  7. Abbott Laboratories $155 2 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $108 5 payments
  9. Amgen Inc. $107 5 payments
  10. Radius Health, Inc. $78 3 payments
  11. Other $186 8 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $2,239 98 payments
Products named General payments · program years 2020–2025
  1. Kerendia $410 18 payments
  2. VERQUVO Cardiovascular $214 9 payments
  3. Ozempic $213 11 payments
  4. FARXIGA $200 10 payments
  5. LEQVIO $199 11 payments
  6. VERQUVO Cardiovascular $171 7 payments
  7. ELIQUIS $145 6 payments
  8. Xience Sierra Coronary Stent System $140 1 payment
  9. LifeVest $108 5 payments
  10. JARDIANCE $74 3 payments
  11. Other $562 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

176

Median for Cardiology: 2,533

Drug cost

$22,552

Median for Cardiology: $485,213

Branded share of claims

8.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 15 $20,607
Metoprolol Succinate Generic 22 $466
Amiodarone Hcl Generic 16 $402
Rosuvastatin Calcium Generic 16 $296
Labetalol Hcl Generic 11 $207
Atorvastatin Calcium Generic 29 $199
Furosemide Generic 14 $171
Amlodipine Besylate Generic 19 $95
Carvedilol Generic 19 $89
Hydrochlorothiazide Generic 15 $20

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$286,276

Medicare's payments for the services billed

Medicare patients

637

Average age 75

Services billed

6,058

326 women, 311 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 70%
Diabetes 68%
Ischemic heart disease 58%
Chronic kidney disease 47%
Arthritis 46%
Atrial fibrillation 40%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $137
$137 — —
ELIQUIS
  • PFIZER INC. $54
  • E.R. Squibb & Sons, L.L.C. $25
$80 15 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $70
$70 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $60
$60 — —
Repatha
  • Amgen Inc. $54
$54 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record